Journal for ImmunoTherapy of Cancer· @jitcancer · X·· 2026-04-21Score60
Body
Immunoprevention continues to gain momentum as O. Nadeem shares, “Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trial” at #AACR26. A #JITC position article from
@sitcancer
explores key challenges and opportunities in this evolving space:
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: Journal for ImmunoTherapy of Cancer · x.com